| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_41afc1b11cbae48ca90470f31ef17c0e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aff6633139e8f79659a0587cc38a6c07 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-104
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-101
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70596
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-102 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-564
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6854
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-686
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-564 |
| filingDate |
2017-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_56f60b4ba9dd61752f284739bcc18567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_980e60a6f3126dd1c16cfcc6fc80970b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b3b1846343d169fd2deff92a32b155a |
| publicationDate |
2020-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020393461-A1 |
| titleOfInvention |
Use of anti-cd26 antibody levels as autoimmune and/or inflammatory disease biomarkers |
| abstract |
The present invention relates to the use of anti-CD26 antibodies as markers for the screening, diagnosis or monitoring of human subjects having, or suspected to have an autoimmune and/or inflammatory disease, such as rheumatoid arthritis, in particular those in an early stage of the disease. More specifically, it refers to an invitromethod for the screening of a subject having, or suspected of having an autoimmune and/or inflammatory disease, such as rheumatoid arthritis, comprising the following steps: a) determining the levels of anti-CD26 IgG antibodies in an antibody-containing sample isolated from said subject; b) comparing the levels in said antibody-containing sample with a reference value; wherein an increase of the anti-CD26 IgG antibody levels in the subject sample with regard to said reference value is indicative of disease; and wherein said reference value corresponds to the anti-CD26 IgG antibody mean levels in healthy subjects. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113009131-A |
| priorityDate |
2016-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |